Market Spotlight: Hidradenitis Suppurativa

Figure 1: Overview of pipeline drugs for HS in the US
Figure 2: Pipeline drugs for HS, by company
Figure 3: Pipeline drugs for HS, by drug type
Figure 4: Pipeline drugs for HS, by classification
Figure 5: Avacopan for HS (October 28, 2020): Phase IIb - AURORA
Figure 6: Key upcoming events in HS
Figure 7: Probability of success in the dermatology-general pipeline
Figure 8: Clinical trials in HS
Figure 9: Top 10 drugs for clinical trials in HS
Figure 10: Top 10 companies for clinical trials in HS
Figure 11: Trial locations in HS
Figure 12: HS trials status
Figure 13: HS trials sponsors, by phase

Table 1: Marketed drugs for HS
Table 2: Pipeline drugs for HS in the US
Table 3: Avacopan for HS (October 28, 2020)
Table 4: Vilobelimab for HS (June 30, 2020)
Table 5: Vilobelimab for HS (November 6, 2019)
Table 6: Historical global sales, by drug ($m), 2015–19
Table 7: Forecasted global sales, by drug ($m), 2021–25